Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

O6-Benzylguanine and Temozolomide in Combination With Genetically Modified Peripheral Blood Stem Cells in Newly Diagnosed Glioblastoma Multiforme

This study has suspended participant recruitment.
(Drugs unavailable)
Sponsor:
Collaborator:
Information provided by (Responsible Party):
Stanton Gerson MD, Case Comprehensive Cancer Center
ClinicalTrials.gov Identifier:
NCT01269424
First received: December 31, 2010
Last updated: July 21, 2014
Last verified: July 2014
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study has suspended participant recruitment.
  Estimated Study Completion Date: No date given
  Estimated Primary Completion Date: June 2015 (Final data collection date for primary outcome measure)